V503 + GARDASIL

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Human Papillomavirus

Conditions

Human Papillomavirus

Trial Timeline

Feb 23, 2011 → Dec 20, 2011

NCT ID

NCT01304498

About V503 + GARDASIL

V503 + GARDASIL is a phase 3 stage product being developed by Merck for Human Papillomavirus. The current trial status is completed. This product is registered under clinical trial identifier NCT01304498. Target conditions include Human Papillomavirus.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03998254	Phase 3	Active	Jun 26, 2019	Mar 31, 2028	Papillomavirus Infections
NCT02653118	Pre-clinical	Active	Jan 22, 2016	Jan 1, 2040	Cervical Cancer
NCT02114385	Phase 3	Completed	Mar 24, 2014	Apr 22, 2015	Papilloma Viral Infection
NCT01304498	Phase 3	Completed	Feb 23, 2011	Dec 20, 2011	Human Papillomavirus

Competing Products

20 competing products in Human Papillomavirus

See all competitors

Product	Company	Stage	Hype Score
Influenza vaccine, split inactivated	Comac Medical	Phase 1	25
CS-8958 + CS-8958 + oseltamivir phosphate	Daiichi Sankyo	Phase 3	77
GSK1265744 30mg + Placebo + GSK1265744 5mg	Shionogi	Phase 2	52
Dolutegravir	Shionogi	Phase 3	77
GSK1349572 + efavirenz	Shionogi	Phase 2	52
Dolutegravir + Rlipivirine + GSK1265744	Shionogi	Phase 1	33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granules	Shionogi	Phase 1	33
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mg	Shionogi	Phase 1	33
GSK1349572 (dolutegravir) + raltegravir	Shionogi	Phase 3	77
Ortho-Cyclen + Dolutegravir + Placebo	Shionogi	Phase 1	33
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusion	Shionogi	Phase 1	33
dolutegravir	Shionogi	Phase 3	77
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placebo	Shionogi	Phase 3	77
GSK1349572 + Efavirenz	Shionogi	Phase 1	33
GSK1349572	Shionogi	Phase 1	33
GSK1349572 + Placebo	Shionogi	Phase 2	52
Dolutegravir + Methadone	Shionogi	Phase 1	33
GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir Placebo	Shionogi	Phase 3	77
GSK1349572 + Rifampin + Rifabutin	Shionogi	Phase 1	33
DTG + BCV + TVR	Shionogi	Phase 1	33

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved